Lupin receives Health Canada approval for Hydrochloride ER capsules

Lupin announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic lnderal - LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin's Pithampur Unit-2 Facility.

Lupin's Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of lnderal LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.

Powered by Capital Market - Live News